What's in Centocor, Inc.'s pipeline?

Centocor, Inc. has 11 drugs in our index: 1 marketed, 0 filed, 5 in Phase 3, 4 in Phase 2, 1 in Phase 1.

Which companies overlap with Centocor, Inc.'s portfolio?

Top competitors by shared drug class: Pfizer, Celltrion, Merck Sharp & Dohme LLC, JHSPH Center for Clinical Trials, Bristol-Myers Squibb.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/centocor-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Centocor, Inc. — Portfolio Competitive Intelligence Brief

Centocor, Inc. pipeline: 1 marketed, 0 filed, 5 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 5 Phase 3 4 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Etanercept 50 mg	Etanercept 50 mg	marketed
Abxicimab	Abxicimab	phase 3			Other
Placebo; golimumab	Placebo; golimumab	phase 3	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)	Immunology
Abciximab; reteplase; abciximab placebo; abciximab	Abciximab; reteplase; abciximab placebo; abciximab	phase 3	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa integrin receptor	Cardiovascular
Methotrexate capsules	Methotrexate capsules	phase 3	Antimetabolite; Folate antagonist	Dihydrofolate reductase (DHFR)	Oncology; Immunology
Placebo (IP)	Placebo (IP)	phase 3

Therapeutic area mix

Immunology · 4
Cardiovascular · 1
Oncology; Immunology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 3 shared drug classes
Celltrion · 3 shared drug classes
Merck Sharp & Dohme LLC · 3 shared drug classes
JHSPH Center for Clinical Trials · 2 shared drug classes
Bristol-Myers Squibb · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
AbbVie (prior sponsor, Abbott) · 2 shared drug classes
Samsung Bioepis Co., Ltd. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Centocor, Inc.:

Cite this brief

Drug Landscape (2026). Centocor, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centocor-inc. Accessed 2026-05-14.